TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $15.9 million versus the consensus estimate of $12.83 million.

• 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Company’s Financial Guidance
• Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Financial Guidance
• Company Launched ANNOVERA, a Novel, Long-Lasting Contraceptive
• Company Expects Full-Year 2020 Net Product Revenue of $90 Million to $110 Million

“I am very pleased with our commercial team’s execution in 2019, which has put us in a strong position for 2020. We ended the year exceeding our fourth quarter net revenue guidance and achieved the top end of our full-year guidance,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “Our goal is to build on this momentum as we make additional investments in our products to generate a significant revenue inflection point in 2020.”

GUIDANCE:

TherapeuticsMD sees FY2020 revenue of $90-100 million, versus the consensus of $100.15 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.